Chimeric Multivalent Polysaccharide Conjugate Vaccines
The present invention provides multivalent chimeric conjugate vaccine molecule and methods of using the conjugate to immunize subjects against bacterial infections. A conjugate molecule of the invention comprises multiple bacterial capsular polysaccharides linked to a carrier protein. Accordingly, the conjugate molecule provides immune protection against multiple types of bacteria in a single vaccines. In particular, conjugate molecules of the invention are used to prevent or attenuate Group B Streptococcus and meningococcal infections.
1 . A multivalent conjugate molecule comprising a carrier protein with bacterial capsular polysaccharides obtained from at least three different types of bacterial capsular polysaccharides covalently linked to the carrier protein, wherein the molecule elicits protective antibodies to each of said different bacterial capsular polysaccharides.
2 . The conjugate molecule of claim 1 comprising four, five, or six different bacterial capsular polysaccharides covalently linked to the carrier protein;
wherein the carrier protein is selected from the group consisting of Cα protein, Cβ protein, tetanus toxoid, diphtheria toxoid, diphtheria toxoid analog CRM197, and a porin protein.
3 - 5 . (canceled)
6 . The conjugate molecule of claim 1 , wherein the bacterial capsular polysaccharides are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type Ia, type Ib, type II, type III, type V, and type VIII; or different Neisseria meningitidis capsular polysaccharides selected from the group consisting of A, B, C, W, and Y.
7 . The conjugate molecule of claim 6 , wherein the bacterial capsular polysaccharides are type Ia, type III and type V Group B Streptococcus capsular polysaccharides, of a size between 80 and 120 kilodaltons, and present in equimolar amounts.
8 - 9 . (canceled)
10 . The conjugate molecule of claim 7 , wherein between about 5 and 20% of the sialic acid residues of the Group B Streptococcus capsular polysaccharides are covalently linked to the carrier protein; and the carrier protein is Cβ protein.
11 - 12 . (canceled)
13 . The conjugate molecule of claim 6 , wherein the bacterial capsular polysaccharides are B, C, and Y Neisseria meningitidis capsular polysaccharides; or C, Y, and W-135 Neisseria meningitidis capsular polysaccharides; and
wherein the carrier protein is a porin protein, tetanus toxoid, or CRM197.
14 - 16 . (canceled)
17 . A method of preparing a multivalent conjugate molecule, the method comprising covalently linking at least three different types of bacterial capsular polysaccharides to a carrier protein.
18 . The method of claim 17 , wherein covalently linking the bacterial capsular polysaccharides to the carrier protein comprises steps of:
(a) oxidizing the polysaccharides; and
(b) coupling the oxidized polysaccharides to the carrier protein, and
wherein the carrier protein is selected from the group consisting of Cα protein, Cβ protein, tetanus toxoid, diphtheria toxoid, diphtheria toxoid analog CRM197, and a porin protein.
19 . The method of claim 18 , wherein the polysaccharides are coupled to the carrier protein by reductive animation using a bispacer coupling with a linker.
20 - 21 . (canceled)
22 . The method of claim 17 , wherein the bacterial capsular polysaccharides are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type Ia, type Ib, type II, type III, type V, and type V; or different Neisseria meningitidis capsular polysaccharide selected from the group consisting of A, B, C, W, and Y.
23 . The method of claim 22 , wherein the bacterial capsular polysaccharides are type Ia, type III, and type V Group B Streptococcus capsular polysaccharides; and the carrier protein is Cβ protein.
24 . (canceled)
25 . The method according to claim 23 , wherein between about 5 and 20% of the sialic acid residues of the bacterial capsular polysaccharides are oxidized and coupled to protein.
26 - 27 . (canceled)
28 . The method of claim 22 , wherein the bacterial capsular polysaccharides are B, C, and Y Neisseria meningitidis capsular polysaccharides; or C, Y, and W-135 Neisseria meningitidis capsular polysaccharides; and
wherein the carrier protein is recombinant porin B, tetanus toxoid, or CRM197.
29 - 31 . (canceled)
32 . A method of preventing or attenuating an infection in a mammal, the method comprising administering to the mammal a multivalent conjugate molecule comprising a carrier protein with at least three different types of bacterial capsular polysaccharides covalently linked to the carrier protein, wherein the multivalent conjugate molecule is administered in an amount sufficient to elicit protective antibodies against the bacterial capsular polysaccharides.
33 . The method of claim 32 , wherein the carrier protein is selected from the group consisting of Cα protein, Cβ protein, tetanus toxoid, diphtheria toxoid, diphtheria toxoid analog CRM197, and a porin protein.
34 . The method of claim 32 , wherein the infection is caused by Group B Streptococcus and the bacterial capsular polysaccharides of the conjugate molecule are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type Ia, type Ib, type II, type III, type V, and type VIII; or
wherein the infection is caused by Neisseria meningitidis and the bacterial capsular polysaccharides of the conjugate molecule are different Neisseria meningitidis capsular polysaccharides selected from the group consisting of A, B, C, W, and Y.
35 . The method of claim 34 , wherein the bacterial capsular polysaccharides are type Ia, type III and type V Group B Streptococcus capsular polysaccharides; and the carrier protein is Cβ protein.
36 - 37 . (canceled)
38 . The method of claim 34 , wherein the bacterial capsular polysaccharides are B, C, and Y Neisseria meningitidis capsular polysaccharides; or C, Y, and W-135 Neisseria meningitidis capsular polysaccharides; and
wherein the carrier protein is recombinant porin B, tetanus toxoid, or CRM197.
39 - 41 . (canceled)
42 . A pharmaceutical composition comprising the multivalent conjugate molecule according to claim 1 ; and
a pharmacological acceptable carrier,
wherein the multivalent conjugate molecule is in an amount sufficient to elicit protective antibodies against the three different bacterial capsular polysaccharides.
43 . The pharmaceutical composition of claim 42 , wherein the carrier protein is selected from the group consisting of Cα protein, Cβ protein, tetanus toxoid, diphtheria toxoid, CRM197, and a porin protein.
44 . The pharmaceutical composition of claim 42 , wherein the bacterial capsular polysaccharides are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type Ia, type Ib, type II, type III, type V, and type VIII; or different Neisseria meningitidis capsular polysaccharides selected from the group consisting of A, B, C, W, and Y.
45 . The pharmaceutical composition of claim 44 , wherein the bacterial capsular polysaccharides are type Ia, type III and type V Group B Streptococcus capsular polysaccharides; and the carrier protein is Cβ protein.
46 - 47 . (canceled)
48 . The pharmaceutical composition of claim 44 , wherein the bacterial capsular polysaccharides are B, C, and Y Neisseria meningitidis capsular polysaccharides; or C, Y, and W-135 Neisseria meningitidis capsular polysaccharides; and
wherein the carrier protein is tetanus toxoid, recombinant porin B, or CRM197.
49 - 51 . (canceled)